Table 1. Demographic characteristics of vaccinees and COVID-19 cases.
| Homologous vaccinees (BNT/BNT) |
Heterologous vaccinees (AZ/ BNT) |
COVID-19 patients | |
|---|---|---|---|
| N | 104 | 11 | 57 |
| Females (%) | 68.3* | 63.6* | 43.9 |
| Median age (min-max) | 41 (20–66) | 31* (26–37) | 51 (32–79) |
| Median days after first dose (IQR) V2 P1 P21 P32 Boost3 |
21 (21–22) 42 (42–43) 102 (99–109) 276 (272–283) 288 (277–289) |
21 (20–22) 91 (90–92) n/a n/a n/a |
n/a |
| Median days after the onset of symptoms (min-max) | n/a | n/a | 35 (7–43) |
| Vaccination reaction (%): None Local4 Systemic5 |
11.5 14.4 74.0 |
0 0 100 |
n/a n/a n/a |
| Severity of disease6 (%) mild (scale 2–3) moderate/severe (scale 4–5) |
n/a n/a |
n/a n/a |
57.9 42.1 |
1 blood sampling was done for 25
241, and
320 of 104 volunteers.
4pain at the vaccination site.
5includes fever, chills, headache, fatigue, nausea, diarrhea, body aches, and nerve pain.
6Clinical severity of COVID-19 patients was classified according to the WHO clinical progression: (2) ambulatory without limitation of activity, (3) hospitalized without oxygen, (4) hospitalized on oxygen therapy by mask or nasal prongs, (5) hospitalized receiving non-invasive ventilation or high-flow oxygen therapy. Mann-Whitney-U test was used to analyze differences in age and Fisher’s exact test was applied to evaluate difference in gender
(* p<0.05, **p<0.01). d = days, IQR = inter quartile range, n.s. = not significant. AZ = AstraZeneca (ChAdOx1-S), BNT = BioNTech/Pfizer (BNT162b2), V2 = three weeks after first vaccination, P1 = two weeks after second vaccination, P2 = three month after first vaccination; P3 = eight months after first vaccination.